PD-1同工型Δ42PD-1介导的免疫抑制是肝细胞癌患者对PD-1阻断治疗耐药的基础
该研究纳入74例肝细胞癌患者(41例未治疗、28例纳武利尤单抗治疗、5例帕博利珠单抗治疗),发现不表达PD-1但表达其同工型Δ42PD-1的T细胞亚群在未治疗患者中占细胞毒性T淋巴细胞的71%,且与肝细胞癌严重程度正相关;抗PD-1免疫检查点阻断后Δ42PD-1+ T细胞频率随时间增加,尤其在疾病进展患者中;抗Δ42PD-1抗体在三种小鼠肝细胞癌模型中抑制肿瘤生长,而纳武利尤单抗未显示此作用。
要点
- 未治疗肝细胞癌患者中Δ42PD-1+ T细胞占细胞毒性T淋巴细胞的71%。
- Δ42PD-1+ T细胞浸润肿瘤并与肝细胞癌严重程度正相关,且较PD-1+ T细胞更耗竭。
- 抗Δ42PD-1抗体在三种小鼠肝细胞癌模型中抑制肿瘤生长,纳武利尤单抗未显示此作用。
核心结论
- 研究揭示了PD-1免疫检查点阻断耐药的一种机制,并鉴定出抗Δ42PD-1抗体可用于肝细胞癌免疫治疗。
研究设计与样本
- 研究纳入74例肝细胞癌患者,分为三个队列:41例未治疗、28例接受纳武利尤单抗治疗、5例接受帕博利珠单抗治疗。
- 分离外周血单核细胞和肿瘤浸润淋巴细胞进行免疫表型分析。
- 通过单细胞RNA测序分析探索Δ42PD-1的功能意义,并通过功能和机制研究进行验证。
- 在肝细胞癌人源化小鼠模型中测定Δ42PD-1单克隆抗体的免疫治疗疗效。
主要发现
- 发现不表达PD-1但表达其同工型Δ42PD-1的独特T细胞亚群,在未治疗肝细胞癌患者中占细胞毒性T淋巴细胞的71%。
- Δ42PD-1+ T细胞浸润肿瘤并与肝细胞癌严重程度正相关,且通过单细胞和功能分析显示较PD-1+ T细胞更耗竭。
- 接受抗PD-1免疫检查点阻断的肝细胞癌患者显示有效的PD-1阻断,但Δ42PD-1+ T细胞频率随时间增加,尤其在疾病进展患者中。
- 肿瘤浸润的Δ42PD-1+ T细胞可能通过Toll样受体4信号通路维持肿瘤发生。
- 抗Δ42PD-1抗体在三种小鼠肝细胞癌模型中抑制肿瘤生长,而纳武利尤单抗未显示此作用。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Immune checkpoint blockade (ICB) has improved cancer treatment, yet why most hepatocellular carcinoma (HCC) patients are resistant to PD-1 ICB remains elusive. Here, we elucidated the role of a programmed cell death protein 1 (PD-1) isoform, Δ42PD-1, in HCC progression and resistance to nivolumab ICB. DESIGN: We investigated 74 HCC patients in three cohorts, including 41 untreated, 28 treated with nivolumab and 5 treated with pembrolizumab. Peripheral blood mononuclear cells from blood samples and tumour infiltrating lymphocytes from tumour tissues were isolated for immunophenotyping. The functional significance of Δ42PD-1 was explored by single-cell RNA sequencing analysis and validated by functional and mechanistic studies. The immunotherapeutic efficacy of Δ42PD-1 monoclonal antibody was determined in HCC humanised mouse models. RESULTS: We found distinct T cell subsets, which did not express PD-1 but expressed its isoform Δ42PD-1, accounting for up to 71% of cytotoxic T lymphocytes in untreated HCC patients. Δ42PD-1+ T cells were tumour-infiltrating and correlated positively with HCC severity. Moreover, they were more exhausted than PD-1+ T cells by single T cell and functional analysis. HCC patients treated with anti-PD-1 ICB showed effective PD-1 blockade but increased frequencies of Δ42PD-1+ T cells over time especially in patients with progressive disease. Tumour-infiltrated Δ42PD-1+ T cells likely sustained HCC through toll-like receptors-4-signalling for tumourigenesis. Anti-Δ42PD-1 antibody, but not nivolumab, inhibited tumour growth in three murine HCC models. CONCLUSION: Our findings not only revealed a mechanism underlying resistance to PD-1 ICB but also identified anti-Δ42PD-1 antibody for HCC immunotherapy.
引用
- Tan Z, Chiu MS, Yang X, et al. Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients. Gut. 2022. PMID: 36450387. doi:10.1136/gutjnl-2022-327133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。